Another oral, next-generation, dual EZH2/EZH1 inhibitor, Tulmimetostat (CPI-0209), is being evaluated in a phase Ib/II clinical trial (NCT05467748) alongside checkpoint (PD-1) blockade with pembrolizumab, enrolling patients with advanced NSCLC who have progressed under first or second-line treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.